TherapeuticsMD (TXMD) Non-Current Debt (2010 - 2021)

TherapeuticsMD (TXMD) has reported Non-Current Debt for 7 consecutive years, with $171.7 million the latest figure, recorded in Q3 2021.

• For the quarter ending Q3 2021, Non-Current Debt fell 27.55% year-over-year to $171.7 million; the trailing twelve-month figure through Sep 2021 stood at $171.7 million (down 27.55% YoY), and the FY2020 full-year result was $237.7 million, up 22.13% from the prior year.
• Non-Current Debt retreated to $171.7 million in Q3 2021 per TXMD's latest filing, from $175.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $243.8 million in Q2 2020 and bottomed at $73.1 million in Q2 2018.
• Historically, Non-Current Debt has averaged $169.2 million across 4 years, with a median of $189.0 million in 2019.
• The sharpest annual moves came in 2020 and 2021: Non-Current Debt surged 231.19% in 2020, then fell 28.11% in 2021.
• Over 4 years, Non-Current Debt stood at $73.4 million in 2018, then surged by 165.24% to $194.6 million in 2019, then rose by 22.13% to $237.7 million in 2020, then slipped by 27.75% to $171.7 million in 2021.
• According to Business Quant data, Non-Current Debt over the past three periods registered $171.7 million, $175.3 million, and $184.0 million for Q3 2021, Q2 2021, and Q1 2021 respectively.